Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2025, Review
2025

Omega‑3 polyunsaturated fatty acids in treatment and prevention of cardiovascular diseases: 616.1:615.272.4

Review
Published 2025-06-04
Evgeniya V. Sсhreiner
Novosibirsk National Research State University; 1 Pirogova Str., Novosibirsk 630090, Russia; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences; 8 Academika Lavrentyeva Str., Novosibirsk 630090, Russia
ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1; ФГБУН «Институт химической биологии и фундаментальной медицины» Сибирского отделения Российской академии наук; Россия, 630090 Новосибирск, ул. Академика Лаврентьева, 8;
https://orcid.org/0000-0003-3606-4068 (unauthenticated)
Valeria I. Bystrova
Novosibirsk National Research State University; 1 Pirogova Str., Novosibirsk 630090, Russia; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences; 8 Academika Lavrentyeva Str., Novosibirsk 630090, Russia
1ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1; ФГБУН «Институт химической биологии и фундаментальной медицины» Сибирского отделения Российской академии наук; Россия, 630090 Новосибирск, ул. Академика Лаврентьева, 8
https://orcid.org/0000-0003-3522-5384 (unauthenticated)
Evgeny A. Pokushalov
Scientific and Medical Company Soloways; 3 Trudovaya Str., Novosibirsk 630099, Russia; Center for New Medical Technologies LLC; 7 Titova Str., Novosibirsk 630048, Russia
Научно-медицинская компания «Soloways»; Россия, 630099 Новосибирск, ул. Трудовая, 3; ООО «Центр новых медицинских технологий»; Россия, 630048 Новосибирск, ул. Титова, 7
https://orcid.org/0000-0002-9494-4234 (unauthenticated)
Dmitry A. Kudlay
Novosibirsk National Research State University; 1 Pirogova Str., Novosibirsk 630090, Russia; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences; 8 Academika Lavrentyeva Str., Novosibirsk 630090, Russia; Sechenov University; 8 bldg. 2, Trubetskaya Str., Moscow 119048, Russia; Lomonosov Moscow State University; 12 Leninskie Gory, Moscow 119234, Russia
ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1; ФГБУН «Институт химической биологии и фундаментальной медицины» Сибирского отделения Российской академии наук; Россия, 630090 Новосибирск, ул. Академика Лаврентьева, 8; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Россия, 119048 Москва, ул. Трубецкая, 8, стр. 2; ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»; Россия, Москва 119234, Ленинские Горы, 1
https://orcid.org/0000-0003-1878-4467 (unauthenticated)

Keywords

omega‑3 polyunsaturated fatty acids
ω‑3 PUFAs
cardiovascular diseases
triglycerides
eicosapentaenoic acid
docosahexaenoic acid
  Full Text

Abstract

Summary. Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have attracted considerable attention for their potential to improve health and cardiovascular disease prognosis. Meta-analyses of randomized controlled trials have demonstrated the beneficial effects of ω-3 PUFAs on cardiovascular disease outcomes for both primary and secondary prevention; ω-3 PUFAs also reduce the risk of cardiovascular conditions, including lowering blood pressure, lipid levels, and inflammation. This article presents current data on the mechanisms of action and significant therapeutic potential of ω-3 PUFAs.

For citation: Sсhreiner E.V., Bystrova V.I., Pokushalov Е.A., Kudlay D.A. Omega-3 polyunsaturated fatty acids in treatment and prevention of cardiovascular diseases. Tromboz, gemostaz i reologiya. 2025;(2):66–74. (In Russ.).

References:

  1. Mason R.P., Sherratt S.C.R., Eckel R.H. Omega-3-fatty acids: do they prevent cardiovascular disease? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101681. DOI: 10.1016/j.beem.2022.101681.
  2. Sherratt S.C.R., Mason R.P., Libby P. et al. Do patients benefit from omega-3 fatty acids? Cardiovasc Res. 2024;119(18):2884–901. DOI: 10.1093/cvr/cvad188.
  3. Kris-Etherton P.M., Harris W.S., Appel L.J.; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747–57. DOI: 10.1161/01.cir.0000038493.65177.94. Erratum in: Circulation. 2003;107(3):512.
  4. Harris W.S., Pottala J.V., Sands S.A., Jones P.G. Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 2007;86(6):1621–25. DOI: 10.1093/ajcn/86.5.1621.
  5. Shahidi F., Miraliakbari H. Marine oils: compositional characteristics and health effects. In: Nutraceutical and Specialty Lipids and their Co-Products. Ed.F. Shahidi. Boca Raton, FL: CRC Press, 2006. 227–50.
  6. Mikhin V.P., Shveinov A.I., Chernyatina M.A. et al. Parameters of arachidonic acid cycle metabolism in patients with acute myocardial infarction on the background of complex therapy of omega-3 polyunsaturated fatty acids. Arhiv” vnutrennej mediciny. 2017;7(6):450–4. (In Russ.). DOI: 10.20514/2226-6704-2017-7-6-450-454.
  7. Shahidi F., Ambigaipalan P. Omega-3 polyunsaturated fatty acids and their health benefits. Annu Rev Food Sci Technol. 2018;9:345–81. DOI: 10.1146/annurev-food-111317-095850.
  8. Fats and fatty acids in human nutrition. Report of an expert consultation. FAO Food Nutr Pap. 2010;91:1–166.
  9. Siscovick D.S., Barringer T.A., Fretts A.M. et al.; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Cardiovascular Disease in the Young et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15): e867-e884. DOI: 10.1161/CIR.0000000000000482.
  10. Kushnikova I.P., Nelidova N.V. Impact of omega-3 polyunsaturated fatty acids on cardiovascular system. Mezhdunarodnyj zhurnal serdca i sosudistyh zabolevanij. 2022;10(36):42–9. (In Russ.).
  11. Sekikawa A., Curb J.D., Ueshima H. et al.; ERA JUMP (ElectronBeam Tomography, Risk Factor Assessment Among Japanese and U.S. Men in the Post-World War II Birth Cohort) Study Group Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol. 2008;52(6):417–24. DOI: 10.1016/j.jacc.2008.03.047.
  12. Fodor J.G., Helis E., Yazdekhasti N., Vohnout B. “Fishing” for the origins of the “Eskimos and heart disease” story: facts or wishful thinking? Can J Cardiol. 2014;30(8):864–68. DOI: 10.1016/j. cjca.2014.04.007.
  13. Jones P.J., Senanayake V.K., Pu S. et al. DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. Am J Clin Nutr. 2014;100(1):88–97. DOI: 10.3945/ajcn.113.081133.
  14. Laidlaw M., Cockerline C.A., Rowe W.J. A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction. Lipids Health Dis. 2014;13:99. DOI: 10.1186/1476-511X-13-99.
  15. O’Connell T.D., Block R. C., Huang S. P., Shearer G. C. ω3-Polyunsaturated fatty acids for heart failure: effects of dose on efficacy and novel signaling through free fatty acid receptor 4. J Mol Cell Cardiol. 2017;103:74–92. DOI: 10.1016/j.yjmcc.2016.12.003.
  16. Lewis E.J. Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA. 2013;309(1):27. DOI: 10.1001/jama.2012.116654.
  17. Kang J.X., Leaf A. The cardiac antiarrhythmic effects of polyunsaturated fatty acid. Lipids. 1996;31 Suppl:S41–4. DOI: 10.1007/BF02637049.
  18. Khasanov A.Kh., Bakirov B.A., Davletshin R.A. et al. Impact of endothelial dysfunction on gender-specific vascular and neurocognitive heterogeneity in multifocal atherosclerosis in elderly patients. Profilakticheskaya medicina. 2019;22(4):129–37. (In Russ.). DOI: 10.17116/profmed201922041129.
  19. Khasanov A.Kh., Bakirov B.A., Davletshin R.A. et al. Clinical features of comorbid cluster and premorbidly manifestations in patients with high vascular risk in the middle age category with the presence of multifocal atherosclerosis. Kardiologiya. 2019;59(7):31–6. (In Russ.). DOI: 10.18087/cardio.2019.7.n599.
  20. Kristensen S.D., Iversen A.B., Schmidt E.B. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids. 2001;36 Suppl:S79–82. DOI: 10.1007/s11745-001-0686-8.
  21. Mozaffarian D., Benjamin E.J., Go A.S. et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics — 2016 update: a report from the American Heart Association. Circulation. 2016;133(4):447–54. DOI: 10.1161/CIR.0000000000000366.
  22. Mori T.A., Burke V., Puddey I.B. et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71(5):1085–94. DOI: 10.1093/ajcn/71.5.1085.
  23. Schwab U., Lauritzen L., TholstrupT. et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food Nutr Res. 2014;58:10.3402/fnr.v58.25145. DOI: 10.3402/fnr.v58.25145.
  24. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56(8):365–79. DOI: 10.1016/s0753-3322(02)00253-6.
  25. Podzolkov V.I., Tarzimanova A.I. The value of omega-3 fatty acids in the prevention of heart rhythm disorders. Racional’naya farmakoterapiya v kardiologii. 2020;16(3):498–502. (In Russ.). DOI: 10.20996/1819-6446-2020-05-01.
  26. Savelieva I., Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5(1):30–41. DOI: 10.1038/ncpcardio1038.
  27. Virtanen J.K., Murus J., Voutilainen S., Tuomainen T.P. Serum longchain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation. 2009;120(23):2315–21. DOI: 10.1161/CIRCULATIONAHA.109.852657.
  28. Calò L., Bianconi L., Colivicchi F. et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45(10):1723–8. DOI: 10.1016/j.jacc.2005.02.079.
  29. Kumar S., Sutherland F., Lee J.M. et al. Effects of high dose intravenous fish oil on human atrial electrophysiology: implications for possible anti- and pro-arrhythmic mechanisms in atrial fibrillation. Int J Cardiol. 2013;168(3):2754–60. DOI: 10.1016/j.ijcard.2013.03.053.
  30. Nodari S., Triggiani M., Campia U. et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation. 2011;124(10):1100–6. DOI: 10.1161/CIRCULATIONAHA.111.022194.
  31. Vassalini M., Verzeletti A., Restori M., De Ferrari F. An autopsy study of sudden cardiac death in persons aged 1–40 years in Brescia (Italy). J Cardiovasc Med (Hagerstown). 2016;17(6):446–53. DOI: 10.2459/JCM.0000000000000234.
  32. Pedersen C.T., Kay G.N., Kalman J. al.; EP-Europace, UK. EHRA/ HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11(10):e166–96. DOI: 10.1016/j.hrthm.2014.07.024.
  33. Oh D.Y., Talukdar S., Bae E.J. et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–98. DOI: 10.1016/j.cell.2010.07.041.
  34. Mach F., Baigent C., Catapano A.L. et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255. DOI: 10.1093/eurheartj/ehz826.
  35. Li G.-R., Sun H.-Y., Zhang X.-H. et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K + currents and Na + current in human atrial myocytes. Cardiovasc Res. 2009;81(2):286–93. DOI: 10.1093/cvr/cvn322.
  36. Ninio D., Murphy K.J., Howe P.R., Saint D.A. Dietary fish oil protects against stretchinduced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol. 2005;16(11):1189–94. DOI: 10.1111/j.1540-8167.2005.50007.x.
  37. Defilippis A.P., Blaha M.J., Jacobson T.A. Omega-3 fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med. 2010;12(4):365–80. DOI: 10.1007/s11936-010-0079-4.
  38. Azuma M.M., Cardoso C.B.M., da Silva C.C. et al. The use of omega-3 fatty acids in the treatment of oral diseases. Oral Dis. 2022;28(2):264–74. DOI: 10.1111/odi.13667.
  39. Elagizi A., Lavie C.J., O’Keefe E. et al. An update on omega-3 polyunsaturated fatty acids and cardiovascular health. Nutrients. 2021;13(1):204. DOI: 10.3390/nu13010204.
  40. Ishihara T., Yoshida M., Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol. 2019;31(9):559–67. DOI: 10.1093/intimm/dxz001.
  41. Stroes E.S.G., Susekov A.V., de Bruin T.W.A. et al. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018;12(2):321–30. DOI: 10.1016/j.jacl.2017.10.012.
  42. Oscarsson J., Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. DOI: 10.1186/s12944-017-0541-3.
  43. Shearer G.C., Savinova O.V., Harris W.S. Fish oil — how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821(5):843–51. DOI: 10.1016/j.bbalip.2011.10.011.
  44. Lorente-Cebrián S., Bustos M., Marti A. et al. Eicosapentaenoic acid inhibits tumour necrosis factor-α-induced lipolysis in murine cultured adipocytes. J Nutr Biochem. 2012;23(3):218–27. DOI: 10.1016/j. jnutbio.2010.11.018.
  45. Xu H.E., Lambert M.H., Montana V.G. et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3(3):397–403. DOI: 10.1016/s1097-2765(00)80467-0.
  46. Pokushalov E., Ponomarenko A., Bayramova S. et al. Evaluating the impact of Omega-3 fatty acid (SolowaysTM) supplementation on lipid profiles in adults with PPARG polymorphisms: a randomized, double-blind, placebo-controlled trial. Nutrients. 2023;16(1):97. DOI: 10.3390/nu16010097.
  47. Ballantyne C.M., Bays H.E., Braeckman R.A. et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C–III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10(3):635–645.e1. DOI: 10.1016/j. jacl.2016.02.008.
  48. Grevengoed T.J., Trammell S.A., Svenningsen J.S. et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. J Clin Invest. 2021;131(6): e143861. DOI: 10.1172/JCI143861.
  49. Brosolo G., Da Porto A., Marcante S. et al. Omega-3 fatty acids in arterial hypertension: is there any good news? Int J Mol Sci. 2023;24(11):9520. DOI: 10.3390/ijms24119520.
  50. Appel L.J., Miller E.R., Seidler A.J., Whelton P.K. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993;153(12):1429–38.
  51. Morris M.C., Sacks F., Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88(2):523–33. DOI: 10.1161/01.CIR.88.2.523.
  52. Geleijnse J.M., Giltay E.J., Grobbee D.E. et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493–9. DOI: 10.1097/ 00004872-200208000-00010.
  53. Dickinson H.O., Mason J.M., Nicolson D.J. et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215–33. DOI: 10.1097/01.hjh.0000199800.72563.26.
  54. Campbell F., Dickinson H.O., Critchley J.A. et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20(1):107–20. DOI: 10.1177/2047487312437056.
  55. Miller P.E., Van Elswyk M., Alexander D.D. Long-chain omega-3 fatty acids eicosapen-taenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(27):885–96. DOI: 10.1093/ajh/hpu024.
  56. AbuMweis S., Jew S., Tayyem R., Agraib L. Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet. 2018;31(1):67–84. DOI: 10.1111/jhn.12493.
  57. Guo X.F., Li K.L., Li J.M., Li D. Effects of EPA and DHA on blood pressure and inflammatory factors: a meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2019;59(20):3380–93. DOI:10.1080/10408398.2018.1492901.
  58. Musazadeh V., Kavyani Z., Naghshbandi B. et al. The beneficial effects of omega-3 polyunsaturated fatty acids on controlling blood pressure: an umbrella meta-analysis. Front Nutr. 2022;18:985451. DOI: 10.3389/fnut.2022.985451.
  59. Zhang X., Ritonja J.A., Zhou N. et al. Omega-3 polyunsaturated fatty acids intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2022;11(11):e025071. DOI: 10.1161/JAHA.121.025071.